treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston-area clinics are spotlighting ketamine for depression and anxiety. Here's what their approach means for patients using at-home ketamine troches.
TMS vs. Ketamine: What TRD Patients Should Know
Medical Daily covers when to try ketamine or TMS for treatment-resistant depression. Here's what it means for patients weighing ketamine troches.
Esketamine Clinic Protocols: What Troche Patients Should Know
New esketamine clinic-protocol guidance shows why sublingual ketamine troches stay a flexible, accessible alternative for many treatment-resistant patients.
NMDA Side Effects: What the Data Means for Troche Users
New research on NMDA antagonist side effects and discontinuation rates offers practical guidance for ketamine troche patients managing treatment-resistant depression.
Ketamine Dropout Rates: The Case for Troche Optimization
New clinical data on NMDA antagonist side effects and dropout rates reveals why troche dosing flexibility may improve long-term treatment adherence.
Ketamine Dropout Rates: Why Delivery Format Changes Everything
New clinical data on NMDA antagonist side effects and dropout rates shows why ketamine troche delivery may offer a meaningful tolerability advantage.
Side Effects & Stopping Rates: What NMDA Data Means
New data on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients managing treatment-resistant depression.
Ketamine Side Effects: What New Data Means for Troches
New 2026 NMDA-antagonist data on troche side effects and discontinuation rates: how ketamine troches compare on safety and tolerability vs other formats.
NMDA Antagonist Side Effects: What Troche Users Should Know
New research compares side effect profiles and dropout rates across NMDA antagonists. Here's what it means for ketamine troche patients in 2026.
NMDA Antagonist Side Effects: What Troche Users Need to Know
New clinical guidance on NMDA antagonist side effects and discontinuation rates has direct implications for ketamine troche patients. Here's what it means for your treatment.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights glutamate-targeting treatments for TRD, including esketamine and ketamine troches. Here's what it means for your care plan.
NMDA Side Effects: What Troche Users Need to Know
New clinical data on NMDA receptor antagonist side effects and dropout rates—and what it means for ketamine troche dosing and monitoring routines.
Esketamine vs. Troches: What TRD Patients Should Know
A new clinical review on esketamine for TRD highlights access barriers and patient preferences — here's what it means for ketamine troche therapy.
Esketamine TRD Access Gaps Open Doors for Troches
New clinician data on esketamine for TRD reveals access barriers that make compounded ketamine troches a practical frontline option for many patients.
Glutamate Pathways Are Reshaping TRD Treatment
A 2026 review highlights how glutamate-targeting drugs like esketamine and ketamine troches are redefining treatment-resistant depression care.
Glutamate Pathway Treatments Reshape TRD Care
New research highlights glutamate-based treatments for treatment-resistant depression. Here's what it means for ketamine troche patients in 2026.
Contact Ketamine Troche
Send corrections, provider questions, or advertising inquiries.